30 Aug 24
tranScrip announces the retirement of Paul Branthwaite, Principal Client Liaison, after 16 years of outstanding service. As one of the original partners of the company, Paul has played an instrumental role in shaping tranScrip into the trusted partner it is today, particularly among our larger pharmaceutical clients.
Throughout his tenure, Paul has been a cornerstone of tranScrip’s success. His vast network of connections and rich experience in the life sciences industry have been pivotal in positioning tranScrip as the specialist pharmaceutical consultancy of choice. His strategic vision and ability to cultivate lasting relationships have significantly contributed to the growth and reputation of the company.
In addition to his business development achievements, Paul has been a source of inspiration and guidance for new members of the business development team. His commitment to sharing knowledge and fostering growth has helped shape the careers of numerous team members and has left a lasting impact on the company.
“After 45 years in pharma and in my 71st year, it’s time for me to pass on the baton to the next generation”, said Paul Branthwaite. “It has been a journey, and I have been part of many successes, alongside some failures (which teaches you more), but all in all, I hope I have added value. To everyone who has worked with me, or with whom I have interacted over the years, I wish you every success for the future.”
“Paul’s contributions to tranScrip have been invaluable,” said Mark Corbett, CEO of tranScrip. “His dedication, passion and mentorship have left a lasting impact on our team and the business as a whole. We are deeply grateful for his years of service and wish him all the best in his retirement.”
“Paul’s retirement marks the end of the beginning, not only of tranScrip but of the emergence of the consultancy sector in life sciences to which he has contributed so much,” said Flic Gabbay, Senior Vice President and a Founder of tranScrip. “His leadership, commitment and deep understanding of the industry have been invaluable in tranScrip; driving strategy, business growth and mentoring many careers. Paul is a hard act to follow, and his legacy will be felt for years to come as tranScrip, and the sector continue to grow.”
Paul’s retirement will officially take effect on August 31st. As we turn the page to an exciting new chapter at tranScrip, Paul’s remarkable legacy will remain a guiding force, inspiring our team to reach new heights and fuelling the company’s continued success.
Our experienced physicians and scientists, together with our regulatory, clinical and commercial experts can support you to maximise the value of your products. Whatever your project requires, we have the expertise to meet your needs.